The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1319
ISSUE1319
August 24, 2009
Insulin Glargine (Lantus) and Cancer Risk
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Insulin Glargine (Lantus) and Cancer Risk
August 24, 2009 (Issue: 1319)
Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of cancer.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.